NCT05469893View on ClinicalTrials.gov

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2030

Conditions
High-risk Smoldering Multiple MyelomaSmoldering Multiple MyelomaMultiple Myeloma
Interventions
DRUG

Teclistamab

Intravenous (IV) dosage and timing per protocol design

DRUG

Lenalidomide

Oral, dosage and timing per protocol design

DRUG

Dexamethasone

Oral, dosage and timing per protocol design

Trial Locations (3)

80218

RECRUITING

Colorado Blood Cancer Institute, Denver

97239

RECRUITING

Oregon Health & Science University, Portland

02115

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Irene Ghobrial, MD

OTHER